Edwards Lifesciences (EW) Barclays 28th Annual Global Healthcare Conference summary

Growth strategy and business drivers

• Focus on double-digit organic sales growth through differentiated technologies for large patient populations.

• TAVR remains a cornerstone, with TMTT and surgical businesses contributing to growth.

• TMTT expected to reach $2 billion in revenue by 2030, growing 35%-45% in 2026.

• TAVR projected to grow mid to high single digits annually, with surgical and new structural heart initiatives supporting overall growth.

• Toolkit approach with repair and replacement therapies for mitral and tricuspid regurgitation expands physician options.

Innovation and product pipeline

• SAPIEN M3, the first transcatheter transfemoral mitral replacement device, addresses complex anatomy and is now approved in multiple geographies.

• Combination of PASCAL, EVOQUE, and SAPIEN M3 provides comprehensive solutions for mitral and tricuspid disease.

• New growth opportunities include Innovalve for mitral and heart failure therapies like Cordella and Vectorious.

• Acquisition of aortic regurgitation technology aims to develop catheter-based replacement solutions.

Heart failure and comprehensive care

• Expansion into structural heart failure leverages expertise from mitral and tricuspid therapies.

• Cordella and Vectorious form the foundation for heart failure management, targeting patients lacking effective options.

• Long-term vision includes multi-device, multi-therapy solutions for patients at risk of heart failure.

• Emphasis on understanding interplay between structural heart conditions and heart failure progression.